million was reserved for intramural research and $231 million was allocated for cancer prevention and control.
NCI has appeared to prioritize extramural spending on traditional R01 grants (increasing allocations for R01 grants from $356 million in FY 1986 to $377 million in FY 1989, even though the number of such grants declined from 2,508 to 2,239), outstanding investigator grants (increasing spending from $23.2 million in FY 1986 to nearly $53 million in FY 1989), cooperative agreements (doubling spending of $10 million in FY 1986 to $20 million by FY 1989), and intramural research (increasing spending from nearly $214 million in FY 1986 to $294 million by FY 1989; National Cancer Institute, 1998e). (See Box 3-1 for a description of common NIH research grant mechanisms.)
By FY 1993, NCI's budget topped $2 billion for the first time, allowing the Institute to increase funding for R01 grants to $430 million (although the number of grants awarded decreased again to 1,955), increasing MERIT awards from $32 million in FY 1989 to $51.6 million in FY 1993, increasing spending on cancer control contracts from $33 million in FY 1989 to more than $52 million in FY 1993, and nearly doubling the cancer career grant program over FY 1989 levels to $14 million (National Cancer Institute, 1998e).
Congressional appropriations for NCI topped $2.38 billion in FY 1997 and fueled increases in both funding and the number of R01 grants made by the institute (more than $577 million was applied to 2,194 awardees). The number and amount allocated for First Independent Research Support